We are live on ! Find out more
ALGS icon

Aligos Therapeutics
ALGS

68 hedge funds and large institutions have $484M invested in Aligos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 10

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

19% more funds holding

Funds holding: 57 → 68 (+11)

0.1% more ownership

Funds ownership: 2.83% → 2.93% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

12% less capital invested

Capital invested by funds: $550M → $484M (-$66.3M)

Holders
68
Holders Change
+11
Holders Change %
+19.3%
% of All Funds
1.19%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
17
Increased
29
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$27.7M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$15.4M
3
BBA
Baker Bros. Advisors
New York
+$7.38M
4
Morgan Stanley
Morgan Stanley
New York
+$7.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.62M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$8.32M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.48M
3
ACP
Acuta Capital Partners
California
-$4.37M
4
CAM
Cormorant Asset Management
Massachusetts
-$3.77M
5
SI
Sofinnova Investments
California
-$628K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$1.3M -$202K -510 -13%
Millennium Management
27
Millennium Management
New York
$1.08M +$1.11M +2,798 New
Swiss National Bank
28
Swiss National Bank
Switzerland
$872K +$358K +904 +67%
Renaissance Technologies
29
Renaissance Technologies
New York
$825K +$842K +2,128 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$752K +$48.7K +123 +7%
Bank of America
31
Bank of America
North Carolina
$522K +$269K +679 +101%
ACM
32
Altium Capital Management
New York
$519K +$530K +1,340 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$498K +$98.5K +249 +24%
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$423K +$791 +2 +0.2%
State of Wisconsin Investment Board
35
State of Wisconsin Investment Board
Wisconsin
$377K +$56.6K +143 +17%
Goldman Sachs
36
Goldman Sachs
New York
$368K -$225K -570 -38%
HP
37
Harbourvest Partners
Massachusetts
$291K – – –
SAM
38
Sectoral Asset Management
Quebec, Canada
$262K – – –
Two Sigma Advisers
39
Two Sigma Advisers
New York
$256K +$261K +660 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$253K +$1.58K +4 +0.6%
JF
41
Jump Financial
Illinois
$250K +$255K +644 New
AG
42
Algert Global
California
$250K +$256K +646 New
JP Morgan Chase
43
JP Morgan Chase
New York
$244K -$162K -409 -39%
EMG
44
ETF Managers Group
New Jersey
$236K +$68K +172 +38%
GSWM
45
Golden State Wealth Management
California
$230K – – –
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$211K +$16.6K +42 +8%
CS
47
Credit Suisse
Switzerland
$211K +$216K +545 New
Manulife (Manufacturers Life Insurance)
48
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$190K +$19K +48 +11%
AIG
49
American International Group
New York
$179K +$16.2K +41 +10%
SG Americas Securities
50
SG Americas Securities
New York
$130K +$133K +335 New
1
2
3

ALGS Hedge Fund Activity: Q3 2021 in Review

68 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2021, worth a combined $484M — down 12% from $550M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new ALGS positions and 6 closed out — a net gain of 11 holders — while 29 added to existing stakes and 10 trimmed.

The largest buyer was Logos Global Management, adding an estimated $27.7M. The largest seller was VR Adviser, exiting entirely with an estimated $8.32M sold.

  • 68 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2021, up from 57 in Q2 2021.
  • Funds reported $484M of Aligos Therapeutics stock for Q3 2021, down 12% quarter-over-quarter.
  • 17 funds opened new Aligos Therapeutics positions in Q3 2021 and 6 closed out, a net change of +11 holders.
  • The largest Aligos Therapeutics buyer in Q3 2021 was Logos Global Management, an estimated $27.7M added.
  • The largest Aligos Therapeutics seller in Q3 2021 was VR Adviser, an estimated $8.32M sold.

Based on aggregated 13F filings for Q3 2021.